Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA
vaccines updated for fall 2023 in adults aged≥ 18 years over a 1-year analytic time horizon …

In their letter to the editor, Hannah Volkman and colleagues raise questions about the meth‑
odology used in our recent systematic literature review and meta‑analysis of the …

Waning antibody responses after COVID-19 vaccination combined with the emergence of
the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a …

Introduction Recent data have shown elevated infection rates in several subpopulations at
risk of SARS-CoV-2 infection and COVID-19, including immunocompromised (IC) …

Second, the authors set out to compare mRNA-1273 and BNT162b2, so they should have
included only head-to-head VE estimates. Comparative estimates better account for …

Background/Objectives COVID-19 continues to pose a significant burden that impacts public
health and the healthcare system as the SARS-CoV-2 virus continues to evolve. Regularly …

Abstract The newly identified XBB. 1.16‐containing sublineages, including XBB. 1.5, have
become the prevailing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …

This analysis estimates the economic and clinical impact of a Moderna updated COVID-19
mRNA Fall 2023 vaccine for adults≥ 18 years in Japan. A previously developed …

Objectives To assess the potential clinical impact and cost-effectiveness of coronavirus
disease 2019 (COVID-19) mRNA vaccines updated for Autumn 2023 in adults aged≥ 60 …

The level of neutralizing antibodies required to confer protection against COVID-19
breakthrough infections (BIs) is unclear, and the ability to know the immune status of …